Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Convertible Debt: 2016-2020

Historic Convertible Debt for Rocket Pharmaceuticals (RCKT) over the last 4 years, with Dec 2020 value amounting to $35.1 million.

  • Rocket Pharmaceuticals' Convertible Debt fell 22.38% to $35.5 million in Q1 2021 from the same period last year, while for Mar 2021 it was $35.5 million, marking a year-over-year decrease of 22.38%. This contributed to the annual value of $35.1 million for FY2020, which is 22.16% down from last year.
  • Rocket Pharmaceuticals' Convertible Debt amounted to $35.1 million in FY2020, which was down 22.16% from $45.0 million recorded in FY2019.
  • Rocket Pharmaceuticals' Convertible Debt's 5-year high stood at $49.0 million during FY2016, with a 5-year trough of $35.1 million in FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Convertible Debt value was $41.4 million (recorded in 2018), while the average stood at $40.5 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first increased by 8.69% in 2019, then declined by 22.16% in 2020.
  • Yearly analysis of 4 years shows Rocket Pharmaceuticals' Convertible Debt stood at $49.0 million in 2016, then reached $41.4 million in 2018, then rose by 8.69% to $45.0 million in 2019, then fell by 22.16% to $35.1 million in 2020.